Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been given a consensus recommendation of “Moderate Buy” by the nineteen ratings firms that are presently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $48.71.

Several equities analysts have recently weighed in on NTLA shares. Oppenheimer reduced their price target on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Robert W. Baird reduced their price objective on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Citigroup reduced their price target on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, The Goldman Sachs Group cut their target price on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 14th.

Insider Transactions at Intellia Therapeutics

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 28,735 shares of company stock worth $349,909 in the last 90 days. 3.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Eastern Bank purchased a new stake in Intellia Therapeutics in the 3rd quarter worth approximately $41,000. Values First Advisors Inc. purchased a new stake in shares of Intellia Therapeutics in the third quarter worth $54,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after purchasing an additional 794 shares during the period. KBC Group NV raised its position in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after purchasing an additional 1,020 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Intellia Therapeutics by 182.7% in the 3rd quarter. Blue Trust Inc. now owns 4,189 shares of the company’s stock worth $94,000 after buying an additional 2,707 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Price Performance

NASDAQ:NTLA opened at $10.12 on Thursday. Intellia Therapeutics has a one year low of $9.25 and a one year high of $34.87. The company’s 50-day simple moving average is $12.41 and its 200 day simple moving average is $17.78. The firm has a market capitalization of $1.03 billion, a P/E ratio of -1.86 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. During the same quarter in the previous year, the company earned ($1.38) EPS. The business’s quarterly revenue was down 24.1% on a year-over-year basis. On average, equities research analysts expect that Intellia Therapeutics will post -5.09 earnings per share for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.